Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 17/20 | 0.78 |
| ▸ | MAPK9 | P45984 | 17/20 | 0.78 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.78 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.60 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
| ▸ | CCNH | P51946 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924257 | 0.87 | MAPK8 (1.00) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL29403524 | 0.87 | MAPK8 (1.00) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL14979763 | 0.87 | MAPK8 (1.00) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL16171317 | 0.78 | MAPK8 (0.81) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL29453371 | 0.77 | MAPK8 (0.87) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL22095472 | 0.77 | MAPK8 (0.87) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL22095474 | 0.77 | MAPK8 (0.87) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL22106110 | 0.76 | MAPK8 (0.88) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL22106042 | 0.76 | MAPK8 (0.88) | MAPK8MAPK9MAPK10PIKFYVECDK7 | |
| SCHEMBL22095486 | 0.75 | MAPK8 (1.00) | MAPK8MAPK9MAPK10PIKFYVECDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.